An Innovative Image Guided Radiofrequency Ablation System to treat Atrial Fibril...
An Innovative Image Guided Radiofrequency Ablation System to treat Atrial Fibrillation
Medlumics innovation, AblaView™ is an optically guided radiofrequency (RF) ablation catheter to treat atrial fibrillation and arrhythmias. The AblaView™ technology is based on Optical Coherence Reflectometry) which in turn allows...
ver más
MEDLUMICS
El desarrollo, producción y comercialización de equipos y programas informáticos para aplicaciones médicas. se excluyen de este objeto todas...
TRL
4-5
| 1M€
Fecha límite participación
Sin fecha límite de participación.
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto ABLAVIEW
Duración del proyecto: 48 meses
Fecha Inicio: 2019-04-12
Fecha Fin: 2023-04-30
Líder del proyecto
MEDLUMICS
El desarrollo, producción y comercialización de equipos y programas informáticos para aplicaciones médicas. se excluyen de este objeto todas...
TRL
4-5
| 1M€
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Medlumics innovation, AblaView™ is an optically guided radiofrequency (RF) ablation catheter to treat atrial fibrillation and arrhythmias. The AblaView™ technology is based on Optical Coherence Reflectometry) which in turn allows the Electrophysiologist to view the ablation of precise areas of the myocardial tissue inside the heart in real time for the treatment of Atrial fibrillation.
Atrial Fibrilation is the most common type of heart arrhythmia. An estimated 33.5 million people worldwide suffered from AF and prevalence of the disease is expected to increase as the number of people over the age of 65 continues to expand. There were 491.000 catheter-based procedures carried out worldwide in 2015.
AblaView is a first-in-class optically guided radio-frequency ablation system to provide missing information about the local catheter environment and directly assess lesion progress in real time by probing the tissue surrounding the ablation electrode.
The key disruptive nature of MedLumics’ AblaView™ technology is both been able to precisely control and visualize in real-time tissue ablation at the desired sites of AF propagation but without over-treatment or indeed ablation of healthy tissue. The current technologies do not allow for this level of control or visualization and consequently expose the AF patient to inappropriate ablations and serious side effects or adverse events.
MedLumics’ technology addresses exactly that problem with its AblaView catheter: it will provide the clinicians with direct, real-time information on lesion formation in the tissue surrounding the catheter’s radiofrequency electrode during the ablation process. Although AF patients are expected to benefit most from this innovation, AblaView is also expected to improve the accuracy of other arrhythmia ablation procedures.